Iambic's CEO Tom Miller discusses the company's approach to AI drug discovery (hint: it's way more than protein folding), and highlights the company's clinical HER2 program, and two others on the way
Already this year Chai Discovery has raised a $130M series B and struck a discovery partnership with Eli Lilly - Co-Founder Jack Dent describes how Chai is using AI to design antibodies
CellCentric has kicked off dosing of its first registration-supporting study for the oral p300/CBP inhibitor inobrodib in multiple myeloma today



BiotechTV - News